Evidence map›Paper›PMID 40071193›Full record

ArticleHCA healthcare journal of medicine2025

Extended-Release Buprenorphine Could Overcome Barriers to Medical Treatment of Opioid Use Disorder in At-Risk Populations.

Scott A Davis, Genevieve Verrastro, E Blake Fagan

Abstract readEditorial
In one paragraph

Article in HCA healthcare journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Scott A DavisUniversity of North Carolina Eshelman School of Pharmacy, Asheville, North Carolina.
Genevieve VerrastroMountain Area Health Education Center, Asheville, North Carolina.
E Blake FaganMountain Area Health Education Center, Asheville, North Carolina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Description This article discusses how monthly extended-release buprenorphine can be used to improve the treatment of opioid use disorder (OUD). In particular, the use of monthly extended-release buprenorphine holds promise for patients who have recently been released from jail or prison and are battling OUD, those who are unstable and continue to use opioids illicitly, patients who are experiencing homelessness while also struggling with OUD, and those who are stable and want to be weaned off buprenorphine.

Indexed as

buprenorphinenarcotic antagonistsopiate substitution treatmentopioid-related disordersopioid use disorderOUDvulnerable populations

Identifiers

PMID40071193
PMCPMC11892404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.